Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
Eric J Miller(Tisch Hospital), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Qianqian Zhao(University of Wisconsin Carbone Cancer Center), Bradley Curtis Carthon(Emory University), Suthee Rapisuwon(Georgetown University), Mehmet Asım Bilen(Emory Healthcare), Menggang Yu(University of Michigan), Tracy L. Rose(University of North Carolina at Chapel Hill), Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Xīn Gào(Qingdao University), Neeraj Agarwal(University of Utah), Benjamin L. Maughan(Huntsman Cancer Institute)
Cited by 2
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k